2127 results about "Drug efficiency" patented technology

The invention relates to new use of levo-oxiracetam in pharmaceutical field, and in particular relates to application of levo-oxiracetam in preparation of a medicine for treating memory and intelligence disturbance. The experiment result shows that the levo-oxiracetam is a main active ingredient for playing efficacy in oxiracetam, the clinical dosage can be greatly reduced by singly using the levo-oxiracetam, and the potential toxic and side effect is reduced. According to the invention, the levo-oxiracetam is a single active ingredient, the raw material purity is greater than 99.5% so as to effectively avoid the toxicity risk caused by other impurities in the medicine, the pharmacy is safer, the medicine quality is more controllable, and the curative effect is more precise.

This invention concerns the method of extracting salvianolic acid A from Chinese crude drug: danshen root, and the quality control methods and drug combinations, and the application of this drug. It can be used in the preparation of the prevention drugs for cardiovascular disease, liver damage, liver fibrosis, pulmonary fibrosis and other.

A system for helping a chemist to identify pharmacophoric mechanisms, based on a set of input data representing many chemical compounds. Given an input data set defining for each compound a feature characteristic and an activity characteristic, a computer agglomeratively clusters representations of the molecules based on their feature characteristics. The result of this process is a multi-domain pyramid structure, made up of a number of nodes each representing one or more molecules. For each node, the computer identifies a representative feature set (such as a largest substructure common among the molecules in the node) and a representative activity level (such as an average of the activity levels of the molecules in the node). The computer then provides as output to a chemist a description of all or part of the pyramid. This process thus converts a large set of raw data into an understandable and commercially useful form, which can assist the chemist in developing beneficial new pharmaceuticals.

A method of evaluating drug efficacy of experimental pharmaceutical agents or biological agents proposed for the treatment of arterial plaque burden is described herein. Arterial plaque from a first appendage is removed and analyzed for the content of one or more markers. One or more test pharmaceutical agent or biological agent alone or in combination are administered to the patient for a specified period of time equal to a period of time after which it is supposed that a marker level will have changed in response to the drug. Arterial plaque is then removed from a second appendage and analyzed for the same marker or markers as the first plaque tissue in order to determine whether the test pharmaceutical agent or biological agent was efficacious in altering the production of the marker in the patient.

The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.

The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum/plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.

The invention relates to the technical field of nano materials and specifically relates to amino-modified silica with dual drug-loading effects. According to the technical scheme, firstly, mesoporous silica nanoparticles are prepared by a template method; secondly, surface amino modification is carried out onto the mesoporous silica nanoparticles by 3-aminopropyltriethoxy silane; thirdly, ursolic acid is chemically coupled to the spherical mesoporous silica nanoparticles by amido bonds; and fourthly, the coupled nanoparticles are dispersed in DMF (dimethyl formamide) solution; a proper amount of ursolic acid is added, mixed and stirred; and finally vacuum drying is carried out to obtain the amino-modified silica with dual drug-loading effects. The mesoporous nano material with dual drug-loading effects prepared by the mesoporous silica disclosed by the invention is high in loading rate, can achieve controlled release effect for the loading drug ursolic acid, so that drug effect lasts for a long period time, and therefore, bioavailability of the ursolic acid is greatly improved.

The invention provides a pancreatic cancer marker, and a detection method, a kit and a biochip thereof. The pancreatic cancer marker provided by the invention contains 36 kinds of micro ribonucleic acids which stably exist in the serum/plasma of a person receiving the test and can be detected. The invention also provides a kit and a biochip of tools or elements for detecting the pancreatic cancer marker. The combination, the method, the kit and the biochip provided by the invention can be used for auxiliary diagnosis and differential diagnosis of pancreatic cancers, predication of occurrence and recrudescence of disease complications, evaluation of the curative effect, screening of active ingredients of medicaments, evaluation of pesticide effectiveness and the like, and has the advantages of wide detection range, high sensitivity, low detection cost, readily available raw materials, easy storage of samples and the like; and the method is widely applied to work related to the general survey of pancreatic cancers, improves the specificity and sensitivity which are low in the single marker due to individual difference, obviously increases clinical detection rate of pancreatic cancers and becomes an effective method for early diagnosis of pancreatic cancers.

The invention discloses a construction and prediction method of an integrated drug target prediction system. The method comprises the following steps of: analyzing a protein crystal structure database; selecting the protein bound with the drug-like ligand small molecule or the protein with the small molecule ligand binding potential as a target point, and building a crystal structure database of targets; for these targets, collecting the information of the targets related to diseases, the biology type and the active small molecule ligand information, and integrating a comprehensive target screening database composed of an active site database, a pharmacophore database, a small molecular compound database and a target basic information database. Based on the comprehensive target screening database, the construction of the integrated drug target prediction system is realized through a script program or a PipelinePilot flow, and the probability of target prediction accuracy of the method is provided. The method provided by the invention exerts the three above technical advantages to provide the probability of target prediction, thereby providing effective basis for further experimental verification.

This invention discloses a method for preparing chito-oligosaccharide/seaweed fertilizer composite biological agent. The composite biological agent is composed of: chito-oligosaccharide 0.2-3 wt. %, seaweed fertilizer 0.5-3 wt. % (according to alginic acid weight), buffer solution (pH = 5-8) 1-30 wt. % (according to solute weight), and water as balance. The composite biological agent has improved drug efficiency and fertilizer efficiency, and can prevent and treat plant disease. Besides, the composite biological agent is environmentally friendly.

The invention relates to fusion protein used to prevent and cure I type and II type diabetes and its preparation method and application. It supplies the fusion protein which is formed by glucagon analogy peptide GLP-1, GLP-1 mutant and IgG-Fc, its analogy factor lizard salivary gland polypeptide extendin-4 and IgG-Fc, and the application of the above fusion protein and its DNA used in diabetes prevention and therapy. The fusion protein can increase not only GLP-1 effect, but also the affinity and immunological tolerance of ligand, which is excreted with the form of homogeneity dimmer to improve polypeptide drug effect, overcomes the defect of the GLP-1 for short half-life, and simplifies purification process.

The invention relates to the technical field of compound traditional Chinese preparations, and in particular relates to a quality control method of liuwei wuling tablets. The quality control method is characterized in that 20 different proportion groups are formed by randomly sampling six medicinal materials of the liuwei wuling tablets; a corresponding HPLC fingerprint spectrum is established, and in-vitro anti-hepatic fibrosis activity is measured; and an SPSS software is utilized to analyze, so that a pectrum-effect relationship of in-vitro anti-hepatic fibrosis effect of the liuwei wuling tablets is established. The relatively perfect quality control method is established on the basis of pharmacodynamic substances of the liuwei wuling tablets. Compared with a conventional single-index content measuring method, the quality control method is more comprehensive, scientific and standard, and has the advantages that the content of multiple components is simultaneously measured, so that not only the analysis time is shortened, but also the loss of a solvent is saved.

The invention provides a collagen and a collagen polypeptide, wherein, the weight percentage of hydroxylysine is more than 1.3 percent. The invention also provides the preparation technology and the application of the collagen and the collagen polypeptide. The invention can make full use of inexpensive raw materials including the fish skin and fish scale of tilapias to produce products with high added value. The collagen polypeptide is used for treating arthritis with a definite drug effect, and the clinical dose is considerably less than other collagen polypeptides. The collagen polypeptide can solve the pollution problem of fish skin wastes, and at the same time avoid the risk of infectious diseases which can be caused by the collagen of land animals. The collagen and the collagen polypeptide have the advantages of considerable economic benefits, energy conservation and environmental protection, simple process equipment, low cost and easy industrialization.

The invention relates to a breast cancer detecting marker by utilizing 16 specific tiny ribonucleic acids steadily existing in blood serum and blood plasma of a human body as well as a detecting method, a kit and a biological chip thereof, and the detecting marker can be used in the aspects of diagnosis and differential diagnosis of breast cancer, occurrence and recurrence forecast as well as efficacy assessment of disease complications, screening and therapeutic evaluation of medicinal active ingredients and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, the materials are conveniently taken, the samples are easy to store and the like. The method can be widely used in related work such as breast cancer census, the defects of low specificity and low sensitivity caused by insuperable individual difference of a single marker can be improved and the clinical detectable rate of the breast cancer is notably improved, and is an effective mean of early breast cancer diagnosis.

The invention relates to a preparation method and application of Exendin-4 biologically located and modified by Evans blue (Evans Blue) or derivatives of Evans blue. The product generated after the C terminal of Exendin-4 is specifically modified with Evans blue or derivatives of Evans blue has biological activity similar to Exendin-4 which is not modified but has longer in vivo half-life than the Exendin-4 which is not modified. Based on the significance of the Exendin-4 in treatment of diseases, the invention also discloses application of the Exendin-4 modified by Evans blue or derivatives of Evans blue in preparation of medicines for treating type-II diabetes and myocardial infarction. The Exendin-4 has the advantages of simplicity and convenience in preparation, obvious curative effect, long-lasting and stable drug effect, convenience in storage and the like and has significance in research and development of new drugs for promoting anti-diabetic and anti-infarction high-efficiency treatment.

The invention belongs to the technical field of medicine, and designs and synthesizes a series of disulfide bond-containing micromolecular prodrugs in which carbon chains in different lengths are linked (sulfur atoms in the disulfide bond are respectively located alpha, beta and gamma sites of an ester bond). PTX (Paclitaxel)-CIT (Citronellol) is used as a sample, and a synthesis method is simpleand easy. On the basis, a micromolecular prodrug self-assembly nano-drug delivery system is prepared. The preparation method is simple and convenient, the stability is high, and efficient encapsulation and delivery of drugs are realized. The invention discovers that the disulfide bond has redox dual sensitivity, can be fractured under the action of high-expression ROS (Reactive Oxygen Species) andGSH (Glutathione) of tumor cells, and PTX can be released; particularly, redox dual hypersensitivity is shown by PTX-CIT prodrugs (alpha-PTX-SS-CIT), which are located in the alpha site of a carbonylgroup, of the disulfide bond, the alpha-PTX-SS-CIT prodrugs can be quickly fractured to release the PTX and take effects, an anti-tumor effect of the PTX is remarkably improved, and a wide development prospect is obtained.

The invention belongs to the field of drug nanopreparation, especially relates to a chitosan nanoparticle preparation of ceftiofur sodium, and a preparation method thereof. The chitosan nanoparticle preparation is characterized in that: the preparation comprises 3-7 mg/mL of chitosan, 1.13-2.63 mg/mL of sodium tripolyphosphate and 2-5 mg/mL of ceftiofur sodium. The preparation method adopts an ionic crosslinking method and comprises the following steps: dissolving the chitosan, dissolving the ceftiofur sodium in the sodium tripolyphosphate solution, adding the sodium tripolyphosphate solution containing the ceftiofur sodium to the chitosan solution under magnetic stirring, and the like. According to the present invention, the ceftiofur sodium chitosan nanoparticles have target distribution and slow release property, such that the action time of the drug can be prolonged, the efficacy can be increased, the toxic and side-effect of the drug can be reduced, the antibacterial stability of the drug can be improved; the preparation method has characteristics of simpleness, reliability and controllable quality, and is suitable for the industrial production.

The invention discloses an HSCGF (Human Stem Cell Growth Factor) liposome as well as the preparation and the application thereof. The HSCGF liposome comprises 2.0 to 4.0 percent of HSCGF, 8.0 to 10.0 percent of phosphatide, 2.5 to 3.5 percent of cholesterol and 10 to 25 percent of protecting agents. The HSCGF is prepared into liposome, the activity of the HSCGF is kept effectively, the stability of SCGF (Stem Cell Growth Factor) can be improved obviously, skin can be promoted to absorb and utilize the SCGF, and the HSCGF liposome has the advantages of good affinity, no toxicity or side effects, and wide application range. The anti-wrinkle performance of cosmetics containing the HSCGF coated with the liposome can still be kept well after the stability is examined for three months. The HSCGF liposome is used as raw material and other active materials and auxiliary materials are used as supplements so as to prepare frequently-used medicine forms to illustrate the drug effect of the SCGF, so that the bioavailability can be improved.

The invention belongs to the technical field of medicines and relates to a puerarin nanocrystalline medical composition and a preparation method and application thereof. Specifically, the puerarin composition is a puerarin nanocrystalline composition. The puerarin composition provided by the invention remarkably improves the solubility and bioavailabilityof puerarin and reduces or eliminates the food effect of the medicine, and is good in stability and can be prepared into various common preparation forms easily, the stability and effect of the medicine are improved, so that the composition has good prospect.

The invention discloses a compound long-acting terramycin injection for animals and preparing method, which is characterized by the following: incorporating 50-300g supercidin, 20-60g trimethoprim or di-trimethoprim, 100-700g composite organic dissolvent, 20-100g magnesium chloride or magnesium oxide, 20-160g aminoethyl alcohol, 1g-10g anti-oxidant and surplus as injecting water. This invention possesses the advantages pf good drug effect, long operational time and low cost.

Methods are provided for predicting the effect of a drug given the drug dose and individual patient clinical characteristics. A neural network is trained on samples of clinical data including the observed drug dose and effect on patients, as well as their individual clinical characteristics. The neural network is then validated to ensure that its predictions fall within an acceptable error range. The neural network is used to predict the effect of a given drug dose for a given set of individual patient clinical characteristics. Methods are also provided for predicting the drug dose required to achieve a desired effect. Another neural network is trained on samples of clinical data including the observed drug dose and effect on patients, as well as their individual clinical characteristics. The neural network is then validated to ensure that its predictions fall within an acceptable error range. The neural network is used to predict the dose of a drug dose required to achieve a desired effect for a patient with a given set of individual clinical characteristics. The first neural network is used to generate training data for the second neural network.

The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.

The invention provides a production method for preparing a medicine for treating peptic ulcer by a periplaneta americana extract, comprising the following steps of: A, dissolving, B, diluting, C, filtering and D, filling. A method for extracting the periplaneta americana extract for treating peptic ulcer comprises the following steps of: a, crushing, b, soaking, c, extracting, d, primarily concentrating, e, degreasing and d, secondarily concentrating. In the extraction process, hydrolysis of active substances for treating peptic ulcer in the extract can be prevented, and the curative effect of the medicine can be improved due to reasonable control on each process parameter; by using the medicine prepared by the method, the cure rate of peptic ulcer can achieve more than 55-70%, and the total effective rate of the medicine can achieve 97-99%; and due to addition of glycerol in the medicine solution, the taste of the medicine solution can be improved, and the synergistic effect of the curative effects can be acted together with the periplaneta americana extract for treating peptic ulcer. The production method disclosed by the invention is short in the process route, and capable of reducing production cost and increasing production efficiency.